Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
The Securities & Exchange Commission has filed a complaint in federal court against biopharmaceutical firm Immunosyn, three shareholder companies, and four senior executives. The complaint charges Immunosyn with misleading investors about the regulatory status of SF-1019, a goat-blood-derived biological response modifier being developed by Argyll Biotechnologies, its controlling shareholder. It also charges the executives with making $20 million in insider-trading profits. SEC wants to force the executives to return their profits and pay penalties and to bar them from serving as officers of a public company.
This article has been sent to the following recipient: